Back to Archived Journals » Research and Reports in Nuclear Medicine » Volume 5

Clinical utility of gadobenate dimeglumine in contrast-enhanced MRI of the breast: a review

Authors Luciani ML, Telesca M, Kirchin M, Pediconi F

Received 1 May 2015

Accepted for publication 9 September 2015

Published 25 November 2015 Volume 2015:5 Pages 33—40


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 6

Editor who approved publication: Professor Chyng-Yann Shiue

Maria Laura Luciani,1 Marianna Telesca,1 Miles A Kirchin,2 Federica Pediconi1

1Department of Radiological Sciences, Oncology and Anatomic Pathology, Sapienza University of Rome, Rome, Italy; 2Global Medical & Regulatory Affairs, Bracco Imaging SpA, Milan, Italy

Abstract: Breast magnetic resonance imaging (MRI) is considered the technique with the highest sensitivity for breast cancer detection. Gadobenate dimeglumine is a gadolinium-based contrast agent (GBCA) that is specifically approved in Europe for breast MRI and which has the highest r1 relaxivity among all GBCAs for this indication. In order to improve the diagnostic performance of breast MRI, several intra-individual crossover studies have evaluated gadobenate dimeglumine as a possible GBCA for this application. This review focuses on the role and advantages of gadobenate dimeglumine as a contrast agent for breast MRI by describing the unique properties of this agent and by summarizing published studies.

Keywords: magnetic resonance, breast imaging, oncology, breast, tumor, women's imaging

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]